GoKawiilResearchers are aiming to test the vaccine in outbreak scenarios in Uganda later in 2026.Credit: Glody Murhabazi/AFP via Getty
Four days ago, the first volunteer was vaccinated against Bundibugyo ebolavirus. That is just 68 days after the World Health Organization declared the current Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda a public-health emergency of international concern. By 27 July, officials had confirmed 3,200 cases and 1,405 deaths in the DRC alone.
The vaccine, called ChAdOx1, is being tested in a phase I clinical trial being run by the Oxford Vaccine Group at the University of Oxford, UK. ChAdOx1 uses the same vector platform as used in the Oxford–AstraZeneca COVID-19 vaccine, but carries genetic instructions for Bundibugyo ebolavirus protein. Around 620,000 doses of the vaccine have already been manufactured.
Ebola outbreak: the data that show why researchers are so alarmed
The trial aims to assess the safety of the vaccine and the immune response it generates before larger trials are rolled out in Uganda later this year. Two other vaccines are also in development: an mRNA vaccine developed by Moderna in Cambridge, Massachusetts, which is expected to go into clinical trials next month; and a candidate being developed by the International AIDS Vaccine Initiative that is similar to the WHO-recommended one for the Zaire ebolavirus species. All three vaccines are being funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Teresa Lambe, head of vaccine immunology at Oxford, is the lead scientific investigator for the ChAdOx1 vaccine study. She also co-developed the Oxford–AstraZeneca COVID-19 vaccine.
Nature spoke to Lambe about how the ChAdOx1 vaccine made it into clinical trials so quickly and what comes next.
What was the secret to your speed?
We have been working on vaccines against Ebola virus for quite some time. Several people in the team were involved in the 2013 outbreak, and since then, we’ve been making candidate vaccines against Ebola and other filoviruses.
When the Bundibugyo outbreak was declared a public-health emergency, we actually had in the freezer the right type of genetic sequence to let us make the Bundibugyo virus-specific vaccine really quickly.
... continue reading